Welcome to our dedicated page for CVS HEALTH SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CVS HEALTH's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CVS HEALTH's regulatory disclosures and financial reporting.
CVS Health Corporation: This Form 144 notifies a proposed sale of 7,500 shares of CVS common stock through Merrill Lynch on the NYSE with an aggregate market value of $532,275, scheduled approximately for 08/20/2025. The filer reports that these shares were received as director compensation across multiple grant dates between 2012 and 2022, totaling specific lots of 1,428; 2,222; 1,546; 2,099; and 205 shares. No securities were reported sold in the past three months. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.
CVS Health Corporation filed an 8-K reporting documentation related to a debt offering process. The filing references an Underwriting Agreement dated August 11, 2025 naming Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the underwriters. The forms of four notes with maturities labeled 2032, 2035, 2055 and 2065 are included as exhibits, along with the opinion and consent of Wachtell, Lipton, Rosen & Katz. The cover page Inline XBRL data is noted as filed. The filing is signed by Brian Newman, Executive Vice President and Chief Financial Officer on August 15, 2025.